These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 232918

  • 1. Limitation by hyperphosphataemia of the "prophylactic" use of vitamin D metabolites in the treatment of osteitis fibrosa in patients on chronic haemodialysis.
    de Fremont JF, Sebert JL, Gueris J, Marie P, Coevoet B, Makdassi R, Lambrey G, Meunier P, Fournier A.
    Proc Eur Dial Transplant Assoc; 1979; 16():675-6. PubMed ID: 232918
    [No Abstract] [Full Text] [Related]

  • 2. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency].
    von Herrath D, Kraft D, Schaefer K, Krempien B.
    MMW Munch Med Wochenschr; 1974 Sep 13; 116(37):1573-8. PubMed ID: 4374654
    [No Abstract] [Full Text] [Related]

  • 3. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
    Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ.
    N Engl J Med; 1989 Aug 03; 321(5):274-9. PubMed ID: 2631697
    [Abstract] [Full Text] [Related]

  • 4. [Some topical problems of subtotal parathyroidectomy in patients on haemodialysis].
    Ritz E, Malluche HH, Röher HD, Krempien B, Koch KM, Andrassy K.
    Dtsch Med Wochenschr; 1973 Mar 09; 98(10):484-96. PubMed ID: 4691570
    [No Abstract] [Full Text] [Related]

  • 5. Biological activity of endogenous and exogenous calcitonin in patients with osteitis fibrosa and chronic renal failure.
    Cundy T, Heynen G, Paton S, Ledingham JG, Russell RG, Oliver DO, Kanis JA.
    Proc Eur Dial Transplant Assoc; 1978 Mar 09; 15():524-31. PubMed ID: 740683
    [Abstract] [Full Text] [Related]

  • 6. [Outcome of osseous lesions of hyperparathyroidism in a patient with chronic renal failure treated with high doses of vitamin D].
    Verberckmoes R, Tanghe W, Michielsen P, Vandenbroucke J.
    J Urol Nephrol (Paris); 1970 Sep 09; 76(9):790-7. PubMed ID: 5482082
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of osteitis fibrosa with 1,25-dihydroxycholecalciferol in patients in treatment with periodic hemodialysis. Effects on the hematochemical and radiological picture].
    Docci D, Turci F, Salvi G, Pistocchi E, Pretolani E.
    G Clin Med; 1982 Sep 09; 63(11-12):831-40. PubMed ID: 6897817
    [No Abstract] [Full Text] [Related]

  • 8. The course of secondary hyperparathyroidism during chronic hemodialysis.
    Ritz E, Franz HE, Jahns E.
    Trans Am Soc Artif Intern Organs; 1968 Sep 09; 14():385-8. PubMed ID: 5701561
    [No Abstract] [Full Text] [Related]

  • 9. Renal-nonresponsive, bone-responsive pseudohypoparathyroidism. A case with normal vitamin D metabolite levels and clinical features of rickets.
    Dabbagh S, Chesney RW, Langer LO, DeLuca HF, Gilbert EF, DeWeerd JH.
    Am J Dis Child; 1984 Nov 09; 138(11):1030-3. PubMed ID: 6548601
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Caclium, phosphorus, and bone in renal disease and transplantation.
    Bricker NS, Slatopolsky E, Reiss E, Avioli LV.
    Arch Intern Med; 1969 May 09; 123(5):543-53. PubMed ID: 4888973
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis.
    Ritz E, Krempien B, Mehls O, Malluche H.
    Kidney Int; 1973 Aug 09; 4(2):116-27. PubMed ID: 4790866
    [No Abstract] [Full Text] [Related]

  • 15. Osteitis fibrosa cystica and secondary hyperparathyroidism in multiple myeloma.
    Bains MA, Pardoe LE, Rudin CE.
    Br J Haematol; 2007 Jan 09; 136(2):179. PubMed ID: 17062009
    [No Abstract] [Full Text] [Related]

  • 16. Bone disease and chronic renal failure.
    Bourke E.
    Ir J Med Sci; 1974 Jul 09; 0(0):suppl:72-4. PubMed ID: 4604173
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Marked direct suppression of primary hyperparathyroidism with osteitis fibrosa cystica by intravenous administration of 1,25-dihydroxycholecalciferol.
    Patron P, Gardin JP, Borensztein P, Prigent A, Paillard M.
    Miner Electrolyte Metab; 1989 Jul 09; 15(6):321-5. PubMed ID: 2615719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.